Literature DB >> 12466001

Prospects for the prevention and reversal of type 1 diabetes mellitus.

Nikolai Petrovsky1, Diego Silva, Desmond A Schatz.   

Abstract

Type 1 (insulin-dependent) diabetes mellitus results from selective immune-mediated destruction of pancreatic islet beta cells. Strategies to prevent or reverse the development of diabetes can be divided into three groups, depending on whether they focus on beta-cell protection, regeneration or replacement. Prevention of immune beta-cell destruction involves either halting the immune attack directed against beta cells or making beta cells better able to withstand immune attack, for example, by making them resistant to free radical damage. The recent identification of beta-cell growth factors and development of stem cell technologies provides an alternative route to the reversal of diabetes, namely beta-cell regeneration. Interestingly, stem cell-derived islets appear to be less sensitive to recurrent immune destruction that is normally seen in response to islet transplantation. The last alternative is beta-cell replacement or substitution. This covers a wide range of interventions including human whole pancreas transplantation, xenotransplantation, genetically modified beta cells, mechanical insulin sensing and delivery devices, and the artificial pancreas. This review describes recent advances in each of these research areas and aims to provide clinicians with an idea of where and when an effective strategy to prevent or reverse diabetes development will become available.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466001     DOI: 10.2165/00003495-200262180-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  178 in total

1.  Cytokines suppress human islet function irrespective of their effects on nitric oxide generation.

Authors:  D L Eizirik; S Sandler; N Welsh; M Cetkovic-Cvrlje; A Nieman; D A Geller; D G Pipeleers; K Bendtzen; C Hellerström
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

2.  Melatonin protects against streptozotocin, but not interleukin-1beta-induced damage of rodent pancreatic beta-cells.

Authors:  A K Andersson; S Sandler
Journal:  J Pineal Res       Date:  2001-04       Impact factor: 13.007

3.  Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies.

Authors:  G F Bottazzo; A Florin-Christensen; D Doniach
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

4.  Complete suppression of insulitis and diabetes in NOD mice lacking interferon regulatory factor-1.

Authors:  T Nakazawa; J Satoh; K Takahashi; Y Sakata; F Ikehata; Y Takizawa; S I Bando; T Housai; Y Li; C Chen; T Masuda; S Kure; I Kato; S Takasawa; T Taniguchi; H Okamoto; T Toyota
Journal:  J Autoimmun       Date:  2001-09       Impact factor: 7.094

Review 5.  Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT).

Authors:  D A Schatz; P J Bingley
Journal:  J Pediatr Endocrinol Metab       Date:  2001       Impact factor: 1.634

6.  Autoreactive T cell responses in insulin-dependent (Type 1) diabetes mellitus. Report of the first international workshop for standardization of T cell assays.

Authors:  B O Roep; M A Atkinson; P M van Endert; P A Gottlieb; S B Wilson; J A Sachs
Journal:  J Autoimmun       Date:  1999-09       Impact factor: 7.094

7.  Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children.

Authors:  J C Carel; C Boitard; G Eisenbarth; J F Bach; P F Bougnères
Journal:  J Autoimmun       Date:  1996-12       Impact factor: 7.094

8.  Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes.

Authors:  G Rudy; N Stone; L C Harrison; P G Colman; P McNair; V Brusic; M B French; M C Honeyman; B Tait; A M Lew
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

9.  Prevention of autoimmune diabetes in nonobese diabetic female mice by treatment with recombinant glutamic acid decarboxylase (GAD 65).

Authors:  J M Pleau; F Fernandez-Saravia; A Esling; F Homo-Delarche; M Dardenne
Journal:  Clin Immunol Immunopathol       Date:  1995-07

10.  In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha.

Authors:  S V Pakala; M Chivetta; C B Kelly; J D Katz
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

View more
  4 in total

Review 1.  Immunomodulation with microbial vaccines to prevent type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

2.  Existence of islet regenerating factors within the pancreas.

Authors:  Meghana Kanitkar; Ramesh Bhonde
Journal:  Rev Diabet Stud       Date:  2005-02-10

Review 3.  New potential treatments for protection of pancreatic B-cell function in Type 1 diabetes.

Authors:  S Cernea; P Pozzilli
Journal:  Diabet Med       Date:  2008-11       Impact factor: 4.359

4.  Pax4 Gene Delivery Improves Islet Transplantation Efficacy by Promoting β Cell Survival and α-to-β Cell Transdifferentiation.

Authors:  Keshab R Parajuli; Yanqing Zhang; Alexander M Cao; Hongjun Wang; Vivian A Fonseca; Hongju Wu
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.